Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01146808 · ClinicalTrials.gov registry record · Phase 1
Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver
A Phase 1 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01146808 is a Phase 1 study that has completed, run by Columbia University. The registered enrollment target is 16 participants.
The verdict
NCT01146808, a Phase 1 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the efficacy of adefovir (ADV) in preventing de novo Hepatitis B in patients who receive Hepatitis B core antibody (HBcAb) positive grafts but who are not Hepatitis B Surface antigen (HBsAg) positive prior to transplant (Hepatitis B naive patients). The second objective is to evaluate the efficacy of accelerated vaccination with Hepatitis B in inducing innate immunity, thereby obviating the need for life-long antiviral therapy.
Interventions
- DRUG Adefovir dipivoxil and hepatitis B vaccination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2006-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01146808
The ClinicalTrials.gov registry entry for NCT01146808 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adefovir dipivoxil and hepatitis B vaccination is the first listed.
NCT01146808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01146808 about?
NCT01146808 is a clinical study titled "Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver". The primary purpose of this study is to evaluate the efficacy of adefovir (ADV) in preventing de novo Hepatitis B in patients who receive Hepatitis B core antibody (HBcAb) positive grafts but who are not Hepatitis B Surface antigen (HBsAg) positive prior to transplant (Hepatitis B naive patients). T...
What is the current status of trial NCT01146808?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2006-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01146808?
The interventions under investigation include: Adefovir dipivoxil and hepatitis B vaccination (DRUG).
Who is sponsoring clinical trial NCT01146808?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.